Viatris, the new US pharma created in the 2020 merger of Mylan and Pfizer’s Upjohn off-patent franchise, is selling its biosimilars portfolio to Biocon Biologics for up...
The International Society for Pharmaceutical Engineering (ISPE) announced the 2021 Facility of the Year Awards (FOYA) Category Winners—including two winners of Special...
24.01.2018
- Sandoz, the generics subsidiary of Novartis, is collaborating with Biocon, an India-based biopharmaceuticals producer, to develop, manufacture and commercialize multiple...
07.11.2017
- Sanofi is pursuing another US competitor for alleged breach of the patent for its top-selling diabetes drug insulin glargine (branded as Lantus and Lantus SoloStar), which together...
09.09.2013
- After the rapid slide in India's rupee this year, the message from the country's corporate titans to the government is clear: shape up and fix the problems or more companies will...
30.05.2011
- Doubled-Edged Sword - The emergence of biosimilars has caused very large ripples in the biopharma pond, and has recently been called the most "disruptive technology" of the decade...
